MyMyelomaTeam

Cytokine Release Syndrome (CRS) is a side effect that can occur after certain myeloma treatments, particularly CAR T-cell therapy and bispecific antibodies. It happens when activated T cells release large amounts of immune chemicals, which can cause inflammation and potentially damage tissues.

Symptoms to watch for Show Full Answer

Cytokine Release Syndrome (CRS) is a side effect that can occur after certain myeloma treatments, particularly CAR T-cell therapy and bispecific antibodies. It happens when activated T cells release large amounts of immune chemicals, which can cause inflammation and potentially damage tissues.

Symptoms to watch for include:
- Fever and chills
- Low blood pressure
- Difficulty breathing
- Confusion or disorientation
- Impaired organ function The good news is that most cases of CRS are mild and manageable. Treatments are available to help control it, and medical teams at specialized centers are specifically trained to recognize and respond to CRS quickly.

Because of this risk, CAR T-cell therapy is only offered at certified treatment centers where staff are equipped to handle these reactions. Close monitoring is also required during the first few doses of bispecific antibodies for the same reason.

It's really important to discuss the risks and benefits of these therapies thoroughly with a doctor before starting treatment, so there are no surprises along the way.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

CAR-T Cell Therapy for Multiple Myeloma: What Is It?

Myeloma Treatment Journey: From First Line to Fourth Line